Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
Michael A. Koren*, Leyi Lin, Kenneth H. Eckels, Rafael De La Barrera, Vincent Dussupt, Gina Donofrio, Erica L. Sondergaard, Kristin T. Mills, Merlin Robb, Christine Lee, Oluwaseun Adedeji, Paul B. Keiser, Justin M. Curley, Nathanial K. Copeland, Trevor A. Crowell, Jack N. Hutter, Melinda J. Hamer, Anais Valencia-Ruiz, Janice Darden, Sheila PeelMihret F. Amare, Tsedal Mebrahtu, Margaret Costanzo, Shelly J. Krebs, Gregory D. Gromowski, Richard G. Jarman, Stephen J. Thomas, Nelson L. Michael, Kayvon Modjarrad
Research output: Contribution to journal › Article › peer-review
17Scopus
citations
Fingerprint
Dive into the research topics of 'Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial'. Together they form a unique fingerprint.